IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY

Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery

The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Novo Nordisk weathers pricing pressure, bets big on oral Wegovy

Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices

Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial

The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated